• Read more about IOV-GM1-201

Short Title: IOV-GM1-201

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

Study Number:

IOV-GM1-201

Study Status:

Enrolling

Treatment Agent:

IOV-4001

Resources and Links

National Clinical Trial Identified Number: NCT05361174

Disease:

• Unresectable Melanoma,
• Metastatic Melanoma,
• Stage III Non-small Cell Lung Cancer,
• Stage IV Non-small Cell Lung Cancer

Study Phase:

I/II

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Hematology and Medical Oncology,
• Lung Cancer